TLR-9 agonist immunostimulatory sequence adjuvants linked to cancer antigens

Hidekazu Shirota, Dennis M. Klinman

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


The primary goal of cancer vaccines is to elicit tumor-specific cytotoxic T lymphocytes (CTL) capable of eradicating established tumors and preventing/eradicating their metastatic spread. CpG oligonucleotides (CpG ODN) activate and support the maturation of immune cells, including plasmacytoid dendritic cells and B lymphocytes, that express Toll-like receptor 9 (TLR9) and are capable of presenting tumor antigens to T cells. Thus, CpG ODN are effective vaccine adjuvants. The adjuvant activity of CpG ODN is improved by maintaining them in close physical and temporal proximity to the co-administered vaccine antigen. This work describes a method of chemically conjugating CpG ODN to antigens and/or cancer cells that improve the resulting CTL response.

Original languageEnglish
Pages (from-to)337-344
Number of pages8
JournalMethods in Molecular Biology
Publication statusPublished - 2014


  • Adjuvant
  • CpG oligonucleotide
  • Tumor
  • Vaccine

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics


Dive into the research topics of 'TLR-9 agonist immunostimulatory sequence adjuvants linked to cancer antigens'. Together they form a unique fingerprint.

Cite this